The US FDA has expanded the approval of evinacumab-dgnb (Evkeeza) to include patients aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The drug, which inhibits lipoprotein lipase and endothelial lipase, showed a significant reduction in LDL-cholesterol levels in a study of 20 patients in this age group. Safety and efficacy data were similar to those in older patients with HoFH.
翻譯成其他語言
從原文內容
www.medscape.com
從以下內容提煉的關鍵洞見
by Steve Stiles 於 www.medscape.com 03-22-2023
https://www.medscape.com/viewarticle/990016深入探究